Abstract
Castration-resistant prostate cancer is the second most common cause of cancer death and results in a median survival of less than 2 years. In prostate cancer, fusions between TMPRSS2 and ERG are common. The ERG rearrangement prevalence in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer is unknown. We investigated the frequency of ERG rearrangement in local recurrent castration-resistant prostate cancer compared to distant metastatic prostate cancer, and assessed for associations between androgen receptor (AR) amplification and ERG rearrangement status. Samples from 134 patients diagnosed with prostate cancer (84 local recurrent castration resistant prostate cancer, 55 distant metastatic prostate cancer) were assessed for their ERG rearrangement and AR amplification status by fluorescence in situ hybridization. Statistical analysis was performed using the χ 2 test. We found that the ERG rearrangement occurs at a significantly lower frequency in distant metastatic prostate cancer (25 %) than in local recurrent castration-resistant prostate cancer (45 %). The AR amplification frequencies were 45 and 35 % in local recurrent castration-resistant prostate cancer and distant metastatic prostate cancer, respectively. The ERG rearrangement occurred at a lower frequency in distant metastatic prostate cancer compared to local recurrent castration-resistant prostate cancer.
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Virchows Archiv |
| Jahrgang | 461 |
| Ausgabenummer | 2 |
| Seiten (von - bis) | 157-162 |
| Seitenumfang | 6 |
| ISSN | 0945-6317 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.08.2012 |
Fördermittel
Acknowledgments We thank Christine Beschorner for the exceptional technical support and Veit Scharf for helpful contributions to statistical analyses. This work was supported by a grant of the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG), Emmy-Noether-Program, PE1179/2-1], the Wilhelm-Sander-Stiftung (grant no. 2011.077.1) and the Rudolf-Becker-Foundation to SP, a junior grant of the University Hospital of Tuebingen (fortüne-Programme) to VJS and by a grant of the DFG (WE1104/11-1) and German Cancer Aid (Deutsche Krebshilfe, 107827) to NW.
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „ERG rearrangement in local recurrences compared to distant metastases of castration-resistant prostate cancer“. Zusammen bilden sie einen einzigartigen Fingerprint.Projekte
- 1 Abgeschlossen
-
Emmy Noether-Nachwuchsgruppe: TMPRSS2-ERG Genfusion als neuer Biomarker für Prostatakarzinom-Patienten und Entwicklung eines Urin-Tests zur nicht-invasiven Diagnostik des Prostatakarzinoms mit Genfusion
Perner, S. (Projektleiter*in (PI))
01.01.07 → 31.12.13
Projekt: DFG Einzelprojekte › DFG-Stipendien: Emmy Noether-Programm
Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver